Yao-Chang Xu
Founder, Executive Chairman of the Board & CEODr. Yao-Chang Xu is the Co-founder of the Abbisko Medicine Co., Ltd. (formerly known as Abbisko Cayman Limited) since April 12, 2016 and has been its Executive Chairman and Chief Executive Officer since March 28, 2018. He is the Founder and serves as Chairman, Director and Chief Executive Officer of Abbisko Therapeutics Co. Dr. Xu has vast drug discovery and development experience in top pharmaceutical companies. Dr. Xu has many years of experience in research and development in oncology and other disease areas. From March 2012 to March 2016, Dr. Xu served as the general manager of the Hansoh Pharmaceutical Group Shanghai Research and Development Centre of Shanghai Hansoh BioMedical Co., Ltd. From January 2006 to March 2012, Dr. Xu served as the executive director at Novartis International AG, a pharmaceutical company principally engaged in the development, manufacture and marketing of branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. Dr. Xu began his career at the University of Sherbrooke in Canada as a postdoctoral researcher in 1988. He then worked at BioChem Pharma Inc., a company engaged in new drug research and development for anti-virus and anti-tumor in the early 1990s. Dr. Xu served as senior organic chemist from October 1993 and subsequently Head of Discovery Chemistry Research until January 2006 at Eli Lilly & Company, a pharmaceutical company engaged in the development of pharmaceutical products for treatment in areas of oncology, diabetes, immunology and neurodegeneration. Prior to founding Abbisko, Dr. Xu served as the General Manager of Hansoh Pharmaceutical Company. As the founding head, he built a strong R&D team from blank and was responsible for overseeing all drug discovery programs. He successfully led more than a dozen of innovative programs from discovery to clinical development, spanning oncology, virology, CNS and other diseases. Prior to Hansoh, Dr. Xu served as Executive Director and Head of Chemistry at Novartis China and Director of Chemistry at Eli Lilly in Indiana, USA. Dr. Xu has served as a director at Abbisko Hong Kong since April 2018, a director and the chief executive officer at Abbisko Shanghai since April 2016, a director at Abbisko Wuxi since July 2020 and a director at Abbisko Australia since December 2020, all four of which are wholly-owned subsidiaries of Abbisko Cayman Ltd. He served as an Industrial Alternate Councilor from 2010 to 2012 for American Chemical Society, the Division of Medicinal Chemistry. He is a member of the America Chemistry Society, Medicinal Chemistry Committee of the Chinese Pharmaceutical Association and Organic chemistry. He has published more than 50 international patents and numerous papers in peer-reviewed journals. He served as the reviewers many journals including J. Org. Chem., Org. Lett., JACS, Medicinal Chem. and Tetrahedron Lett. etc. Dr. Xu obtained his Ph.D. in organic chemistry from the University of Chicago in July 1988 and B.S. in Chemistry from Nanjing University in July 1982.
Positions
- Company NameAbbisko Medicine Co., Ltd.Stock Code02256PositionFounder, Executive Chairman of the Board & CEOColleagues
- HYHongping YuCo-Founder, SVP of Chemistry, Chief Scientific Officer & Executive Director
- JJJing JiChief Medical Officer & Executive Director
- JFJia FengVP of HR and Operations & Head of Human Resource
- YLYongyi LiGeneral Counsel
- HSHongbin SunIndependent Non-Executive Director
- HYHoi Yam ChuiIndependent Non-Executive Director
